Amendment to China Patent Law Offer PTA, PTE and Patent Linkage

28 June 2021 PharmaPatents Blog

This update is provided by Fan Li, Director, Patent Attorney, Chemical Patent Department at CCPIT Patent & Trademark Law Office, Beijing, China.

Patent term adjustment (PTA), patent term extension (PTE), and patent linkage were made available in China as of June 1, 2021. While there are certain rules to be finalized and settled, it is advisable that patentees and drug marketing authorization holders (MAHs) take action now. Provided here is a summary of the main elements of PTA, PTE and patent linkage, as well as suggestions on how to leverage such new opportunities.


Amendment to China Patent Law

As the 4th amendment to China Patent Law entered into effect as of June 1, 2021, patent term adjustment (PTA), patent term extension (PTE), and patent linkage are finally available in China. The specific rules will not be finalized for months to come, but the China National Intellectual Property Administration (CNIPA) and National Medical Products Administration (NMPA) have issued interim measures on how to proceed provisionally. It is advisable to request PTA and PTE and list patents according to the current interim rules in order to preserve the opportunity to seek them later under final rules.

Patent Term Adjustment (PTA)

 So far the interim guidance for PTA includes:

  1. Deadline to request PTA - within 3 months after the patent is issued.
  2. Retroactivity - PTA does not apply to patents issued before June 1, 2021. Only patents issued on or after June 1, 2021 may be eligible.
  3. Interim measures - Patentees may file PTA requests for invention patents issued on or after June 1, 2021, but the requests will not be examined until the amended Implementing Regulations are finalized and become effective.

Suggestions: We suggest patent owners consider filing PTA requests for all important patents for invention issued on or after June 1, 2021, if the patents were granted more than four years from the date of filing and more than three years from the date of requesting substantive examination.

Patent Term Extension (PTE)

So far the interim guidance for PTA includes:

  1. Deadline to request PTE - Within three months from the date of approval of the new drug marketing authorization (MA). Failure to meet this deadline will risk losing the opportunity to seek PTE in the future.
  2. Period of PTE - Maximum extension available is 5 years, and the resulting total effective patent term shall not exceed 14 years from the approval for marketing of the new drug.
  3. Drug/patents eligibility requirements - Not finalized yet.
  4. Retroactivity - According to CNIPA, PTE does not apply to drugs approved on or before May 31, 2021, which means that only drugs approved on or after June 1, 2021 may be eligible.
  5. Interim measures - PTE request may be filed before the above deadline but will not be examined until the amended Implementing Regulations are finalized and become effective months later.

Suggestions: We suggest stakeholders consider applying for PTE once any new drug is approved in China, keeping in mind the above-mentioned deadline.

With regard to retroactivity, although CNIPA has said that PTE does not apply to drugs approved on or before May 31, 2021, the CNIPA's decisions are normally subject to judicial review and the courts' attitude on the retroactivity of PTE is not clear yet. Therefore, for very important drugs approved in China before June 1, 2021, it might be worthwhile to consider requesting PTE within the above-mentioned deadline, and, after the PTE application is rejected by CNIPA, appealing to the courts.

Listing the Patents for Patent Linkage

So far the interim guidance for patent linkage includes:

  1. Deadline to list patents - Remains unfinalized.
  2. Listable patents -
    Chemical drugs: patents to API compound, pharmaceutical composition comprising API, and medical use patents.
    Biological products: active ingredient sequence structure patents, and medical use patents.
    Patents to intermediates, metabolites, crystal forms, preparation methods, and detection methods are excluded.
  3. Retroactivity - Remains unsettled. However, drugs approved before June 1, 2021 and patents issued before June 1, 2021 are not explicitly excluded and thus likely to be qualified.
  4. Interim measures - Patent information may be submitted to a patent information registration platform of NMPA.

Suggestions: Since patents that are not listed will not be qualified for patent linkage, we suggest (a) listing all eligible patents as soon as possible for drugs that have been approved; (b) listing any new eligible patent as soon as possible and within 30 days after the patent is issued; and (c) updating patent information that has been submitted within 30 days after the patent information changes.

This blog is made available by Foley & Lardner LLP (“Foley” or “the Firm”) for informational purposes only. It is not meant to convey the Firm’s legal position on behalf of any client, nor is it intended to convey specific legal advice. Any opinions expressed in this article do not necessarily reflect the views of Foley & Lardner LLP, its partners, or its clients. Accordingly, do not act upon this information without seeking counsel from a licensed attorney. This blog is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Communicating with Foley through this website by email, blog post, or otherwise, does not create an attorney-client relationship for any legal matter. Therefore, any communication or material you transmit to Foley through this blog, whether by email, blog post or any other manner, will not be treated as confidential or proprietary. The information on this blog is published “AS IS” and is not guaranteed to be complete, accurate, and or up-to-date. Foley makes no representations or warranties of any kind, express or implied, as to the operation or content of the site. Foley expressly disclaims all other guarantees, warranties, conditions and representations of any kind, either express or implied, whether arising under any statute, law, commercial use or otherwise, including implied warranties of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Foley or any of its partners, officers, employees, agents or affiliates be liable, directly or indirectly, under any theory of law (contract, tort, negligence or otherwise), to you or anyone else, for any claims, losses or damages, direct, indirect special, incidental, punitive or consequential, resulting from or occasioned by the creation, use of or reliance on this site (including information and other content) or any third party websites or the information, resources or material accessed through any such websites. In some jurisdictions, the contents of this blog may be considered Attorney Advertising. If applicable, please note that prior results do not guarantee a similar outcome. Photographs are for dramatization purposes only and may include models. Likenesses do not necessarily imply current client, partnership or employee status.

Insights

Podcast Episode 56: All Things Summer Associate Recruiting
30 July 2021
Foley Career Perspectives
Foley Podcast to Live Panel Discussion
29 July 2021
Foley Career Perspectives
End In Sight for Auto Shortage? Not So Fast
29 July 2021
Dashboard Insights
Legal Updates: Proposed Legislation for Private Foundation Minimum Distribution Requirements
28 July 2021
Legal News: Family Offices
30th Annual Law of Product Distribution & Franchise Seminar
29 September | 7 & 20 October 2021
Milwaukee | Chicago | Dallas
7th National Telehealth Summit
4-5 October 2021
Miami Beach, FL
AHLA Fraud & Compliance Forum
21-22 September 2021
Baltimore, MD
2nd Clinical Trial Agreements Forum
16-17 September 2021
Online Livestream